Trial Outcomes & Findings for Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis (NCT NCT02465450)
NCT ID: NCT02465450
Last Updated: 2018-04-04
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
85 participants
Primary outcome timeframe
84 days of treatment
Results posted on
2018-04-04
Participant Flow
Participant milestones
| Measure |
JBT101 1 mg QD
JBT-101: 1 mg once a day on Days 1-28
|
JBT-101 5 mg QD
JBT-101: 5 mg once a day on Days 1-28.
|
Placebo QD
Placebo: Subjects received placebo on Days 1 - 28.
|
JBT-101 20 mg QD
JBT-101: 20 mg once a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
JBT-101 20 mg BID
JBT-101: 20 mg twice a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
Placebo BID
Placebo administered twice daily.
Subjects in this analysis group received placebo on Days 1 - 28.
|
|---|---|---|---|---|---|---|
|
Treatment Period 1
STARTED
|
26
|
24
|
35
|
0
|
0
|
0
|
|
Treatment Period 1
COMPLETED
|
24
|
23
|
34
|
0
|
0
|
0
|
|
Treatment Period 1
NOT COMPLETED
|
2
|
1
|
1
|
0
|
0
|
0
|
|
Treatment Period 2
STARTED
|
0
|
0
|
0
|
30
|
28
|
23
|
|
Treatment Period 2
COMPLETED
|
0
|
0
|
0
|
27
|
24
|
23
|
|
Treatment Period 2
NOT COMPLETED
|
0
|
0
|
0
|
3
|
4
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
Baseline characteristics by cohort
| Measure |
JBT101 1 mg QD, 20 mg QD, or 20 mg BID
n=26 Participants
JBT-101: 1 mg once a day on Days 1-28 and either 20 mg QD or 20 mg BID on Days 29-84.
|
JBT-101 5 mg QD,20 mg QD, or 20 mg BID
n=24 Participants
JBT-101: 5 mg once a day on Days 1-28 and either 20 mg QD or 20 mg BID on Days 29-84.
|
Placebo QD,20 mg QD, 20 mg BID, or Placebo BID
n=35 Participants
Placebo: Subjects received placebo on Days 1 - 28 and either 20 mg QD, 20 mg BID, or Placebo on Days 29-84.
|
Total
n=85 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
3 Participants
n=7 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
26 Participants
n=99 Participants
|
23 Participants
n=107 Participants
|
33 Participants
n=206 Participants
|
82 Participants
n=7 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Age, Continuous
|
26.9 years
STANDARD_DEVIATION 7.66 • n=99 Participants
|
28.8 years
STANDARD_DEVIATION 10.40 • n=107 Participants
|
29.2 years
STANDARD_DEVIATION 8.55 • n=206 Participants
|
28.4 years
STANDARD_DEVIATION 8.81 • n=7 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
18 Participants
n=206 Participants
|
39 Participants
n=7 Participants
|
|
Sex: Female, Male
Male
|
17 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
46 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
26 Participants
n=99 Participants
|
22 Participants
n=107 Participants
|
35 Participants
n=206 Participants
|
83 Participants
n=7 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
|
Race (NIH/OMB)
White
|
25 Participants
n=99 Participants
|
24 Participants
n=107 Participants
|
33 Participants
n=206 Participants
|
82 Participants
n=7 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
|
Height
|
171.30 cm
STANDARD_DEVIATION 9.724 • n=99 Participants
|
167.75 cm
STANDARD_DEVIATION 9.192 • n=107 Participants
|
167.82 cm
STANDARD_DEVIATION 8.866 • n=206 Participants
|
168.86 cm
STANDARD_DEVIATION 9.259 • n=7 Participants
|
|
Weight
|
66.98 kg
STANDARD_DEVIATION 14.648 • n=99 Participants
|
64.71 kg
STANDARD_DEVIATION 11.032 • n=107 Participants
|
63.81 kg
STANDARD_DEVIATION 11.806 • n=206 Participants
|
65.03 kg
STANDARD_DEVIATION 12.467 • n=7 Participants
|
|
BMI
|
22.735 kg/m^2
STANDARD_DEVIATION 3.8582 • n=99 Participants
|
22.976 kg/m^2
STANDARD_DEVIATION 3.4182 • n=107 Participants
|
22.608 kg/m^2
STANDARD_DEVIATION 3.4672 • n=206 Participants
|
22.751 kg/m^2
STANDARD_DEVIATION 3.5381 • n=7 Participants
|
PRIMARY outcome
Timeframe: 84 days of treatmentPopulation: These adverse events are based on subjects who entered Treatment Period 2 (n=81). The tabulation of adverse events includes all TEAEs.
Outcome measures
| Measure |
JBT-101 5 mg QD
n=24 Participants
JBT-101: 5 mg once a day on Days 1-28.
|
Placebo QD
n=35 Participants
Placebo: Subjects received placebo on Days 1 - 28.
|
JBT-101 20 mg QD
n=30 Participants
JBT-101: 20 mg once a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
JBT-101 20 mg BID
n=28 Participants
JBT-101: 20 mg twice a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
Placebo BID
n=23 Participants
Placebo administered twice daily.
Subjects in this analysis group received placebo on Days 1 - 28.
|
Lenabasum 1 mg QD
n=26 Participants
Lenabasum: 1 mg once a day on Days 1-28
|
|---|---|---|---|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events.
|
13 Participants
|
15 Participants
|
21 Participants
|
19 Participants
|
14 Participants
|
14 Participants
|
SECONDARY outcome
Timeframe: Day 84Plasma concentrations were reported for the lenabasum 20 mg QD, 20 mg BID, and placebo groups only, at Day 84.
Outcome measures
| Measure |
JBT-101 5 mg QD
JBT-101: 5 mg once a day on Days 1-28.
|
Placebo QD
Placebo: Subjects received placebo on Days 1 - 28.
|
JBT-101 20 mg QD
n=27 Participants
JBT-101: 20 mg once a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
JBT-101 20 mg BID
n=24 Participants
JBT-101: 20 mg twice a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
Placebo BID
n=23 Participants
Placebo administered twice daily.
Subjects in this analysis group received placebo on Days 1 - 28.
|
Lenabasum 1 mg QD
Lenabasum: 1 mg once a day on Days 1-28
|
|---|---|---|---|---|---|---|
|
JBT-101 (Lenabasum) Plasma Concentrations on Day 84
|
—
|
—
|
249.77 ng/mL
Standard Deviation 339.938
|
360.80 ng/mL
Standard Deviation 352.772
|
0.00 ng/mL
Standard Deviation 0.00
|
—
|
Adverse Events
JBT101 1 mg QD
Serious events: 1 serious events
Other events: 13 other events
Deaths: 0 deaths
JBT-101 5 mg QD
Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths
Placebo QD
Serious events: 2 serious events
Other events: 15 other events
Deaths: 0 deaths
JBT-101 20 mg QD
Serious events: 3 serious events
Other events: 21 other events
Deaths: 0 deaths
JBT-101 20 mg BID
Serious events: 2 serious events
Other events: 19 other events
Deaths: 0 deaths
Placebo BID
Serious events: 1 serious events
Other events: 14 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
JBT101 1 mg QD
n=26 participants at risk
JBT-101: 1 mg once a day on Days 1-28
|
JBT-101 5 mg QD
n=24 participants at risk；n=26 participants at risk
JBT-101: 5 mg once a day on Days 1-28.
|
Placebo QD
n=35 participants at risk；n=37 participants at risk
Placebo: Subjects received placebo on Days 1 - 28.
|
JBT-101 20 mg QD
n=30 participants at risk
JBT-101: 20 mg once a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
JBT-101 20 mg BID
n=28 participants at risk
JBT-101: 20 mg twice a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
Placebo BID
n=23 participants at risk
Placebo administered twice daily.
Subjects in this analysis group received placebo on Days 1 - 28.
|
|---|---|---|---|---|---|---|
|
Injury, poisoning and procedural complications
hand fracture
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/37 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Infective pulmonary exacerbation of cystic fibrosis
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
5.4%
2/37 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.0%
3/30 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Thrombosis in device
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/37 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
Other adverse events
| Measure |
JBT101 1 mg QD
n=26 participants at risk
JBT-101: 1 mg once a day on Days 1-28
|
JBT-101 5 mg QD
n=24 participants at risk；n=26 participants at risk
JBT-101: 5 mg once a day on Days 1-28.
|
Placebo QD
n=35 participants at risk；n=37 participants at risk
Placebo: Subjects received placebo on Days 1 - 28.
|
JBT-101 20 mg QD
n=30 participants at risk
JBT-101: 20 mg once a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
JBT-101 20 mg BID
n=28 participants at risk
JBT-101: 20 mg twice a day on Days 29 - 84.
JBT-101: Subjects in this analysis group could have received 1 mg, 5 mg, or placebo during Days 1 - 28.
|
Placebo BID
n=23 participants at risk
Placebo administered twice daily.
Subjects in this analysis group received placebo on Days 1 - 28.
|
|---|---|---|---|---|---|---|
|
Infections and infestations
Upper respiratory tract infection
|
7.7%
2/26 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
8.3%
2/24 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.0%
3/30 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.7%
3/28 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
8.7%
2/23 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Infective pulmonary exacerbation of cystic fibrosis
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
11.4%
4/35 • Number of events 4 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
20.0%
6/30 • Number of events 7 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.7%
3/28 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
17.4%
4/23 • Number of events 4 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Nasopharyngitis
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
5.7%
2/35 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Cognitive disorder
|
7.7%
2/26 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
16.7%
4/24 • Number of events 4 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
11.4%
4/35 • Number of events 5 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.7%
3/28 • Number of events 4 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
17.4%
4/23 • Number of events 4 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory tract congestion
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
8.3%
2/24 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum increased
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
8.3%
2/24 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Dry Mouth
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
8.3%
2/24 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
13.3%
4/30 • Number of events 4 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
7.1%
2/28 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Fatigue
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
7.1%
2/28 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Malaise
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
7.1%
2/28 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Pyrexia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Respiratory tract infection
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
8.7%
2/23 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.7%
3/28 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Headache
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Lethargy
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysia
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
5.7%
2/35 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
13.3%
4/30 • Number of events 6 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
10.7%
3/28 • Number of events 3 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Gastroeosophageal reflux disease
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Sinusitis
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Investigations
Weight decreased
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Metabolism and nutrition disorders
Glucose tolerance impaired
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
3.8%
1/26 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Skin and subcutaneous tissue disorders
Sweat discoloration
|
3.8%
1/26 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Immune system disorders
Food allergy
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Immune system disorders
Seasonal allergy
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Migraine
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Nervous system disorder
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Initial insomnia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Surgical and medical procedures
Gastrostomy
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Apathy
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Disorientation
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Irritability
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Psychiatric disorders
Sleep disorder
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Paranasal sinus hypersecretion
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
6.7%
2/30 • Number of events 2 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Sputum discoloured
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Bradykinesia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Hypersomnia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Sinus headache
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Stupor
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Nervous system disorders
Tremor
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Feeling abnormal
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Thirst
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Thrombosis
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Fungal infection
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Gastrointestinal infection
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Viral infection
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Infections and infestations
Viral upper respiratory tract infection
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Injury, poisoning and procedural complications
Bone contusion
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.6%
1/28 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Investigations
Blood glucose increased
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
3.3%
1/30 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Chest discomfort
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
General disorders
Asthenia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.2%
1/24 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/23 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
2.9%
1/35 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
|
Musculoskeletal and connective tissue disorders
Osteopenia
|
0.00%
0/26 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/24 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/35 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/30 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
0.00%
0/28 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
4.3%
1/23 • Number of events 1 • For treatment groups lenabasum 1 mg QD, lenabasum 5 mg QD and placebo QD, adverse events were collected from Days 1 - 28. For treatment groups lenabasum 20 mg QD, lenabasum 20 mg BID and placebo BID, adverse events were collected from Days 29 - 84.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER